Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Alzymologist Oy
OY
Dissolved
Y-tunnus 3162030-9
Leivontie 1-A8
Technical testing and analysis · NACE 7120
Est. 2020
— employees
zymologia.fi
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
EUR 301K
-53% vs 2023
EBITDA margin
-16.7%
-241% vs 2023
Equity ratio
-37.1%
Financial strength
Net profit 2024
EUR -64K
-450% vs 2023
EBITDA — year on year
EUR millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
EUR 301K
-53%
EBITDA
EUR -50K
-241%
Net profit
EUR -64K
-450%
Total assets
EUR 84K
-67%
Equity
EUR -31K
-188%
Employees
—
—
Company information
Legal name
Alzymologist Oy
Y-tunnus number
3162030-9
Legal form
Osakeyhtiö
NACE code
7120 · Technical testing and analysis
Founded
2. lokakuuta 2020
Share capital
EUR 0
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen yksin
Company purpose
laboratorio- ja tutkimusala
Contact
Address
Leivontie 1-A8
Website
zymologia.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Technical testing and analysis
Companies in Kuopio
All Finland companies
Revenue
EUR millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
1M
2023
0M
2024
EBITDA
EUR millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
Income statement
EUR thousands
Item
2021
2022
2023
2024
Revenue
125
383
635
301
Staff expenses
−73
−411
−1 116
−995
EBITDA
25
8
36
−50
Depreciation & amort.
−3
−6
−13
−12
EBIT
21
2
23
−62
Net financials
—
1
−0
−1
Profit before tax
21
3
23
−63
Tax
4
1
5
1
Net profit
17
3
18
−64
Balance sheet
EUR thousands
Item
2021
2022
2023
2024
Total assets
32
110
254
84
Equity
17
19
35
−31
Long-term debt
—
—
0
0
Short-term debt
15
92
218
115
Total debt
15
92
218
115
Financial ratios
5-year trend
EBITDA margin
-16.7%
This company
15.8%
Market median
-206% vs market
2021
2024
Equity ratio
-37.1%
This company
38.2%
Market median
-197% vs market
2021
2024
Return on equity
-6350400.0%
This company
18.4%
Market median
-34513143% vs market
2021
2024
Net profit margin
-21.1%
This company
8.1%
Market median
-360% vs market
2021
2024
Asset turnover
3.58×
This company
1.12×
Market median
+220% vs market
2021
2024
Debt / equity
3.70×
This company
0.62×
Market median
-497% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via PRH / YTJ · Period 2020-10-01 – 2021-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Former (2)
VA
Vera Abramova
Deputy Member
Deputy Member
2020 – 2025
SA
Seija Anneli Virta
Deputy Member
Deputy Member
2025 – 2025
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
MN
Mikko Nivamo
Board of Directors
2025
Former (1)
AS
Alexander Slesarev
Board of Directors
2020 – 2025
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Alzymologist Oy also hold positions in
0
other companies.
Person
Role here
Other companies
Vera Abramova
Deputy Member
0 companies
Seija Anneli Virta
Deputy Member
0 companies
Alexander Slesarev
Board of Directors
0 companies
Mikko Nivamo
Board of Directors
0 companies